As of 2026-10-08, the Fair Value of Pharmala Biotech Holdings Inc (MDMA.CN) is -0.08 CAD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.25 CAD, the upside of Pharmala Biotech Holdings Inc is -130.68%.
With the market price of 0.25 CAD and our fair value calculation, Pharmala Biotech Holdings Inc (MDMA.CN) is not a good investment. Investing in MDMA.CN stocks now will result in a potential loss of 130.68%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-08-31 | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2025-08-31 | 5Y Avg | |
| Net income | -0.99 | -0.78 | -0.82 | -2.18 | -1.19 | |
| YoY growth | 60.72% | 20.88% | -5.62% | -164.11% | -22.03% | |
| Market Cap (mil) | 33.12 |
| P/E | |
| Forward P/E |
| EPS | -0.02 |
| Avg earnings growth rate | -22.03% |
| TTM earnings | -1.63 |